Information Provided By:
Fly News Breaks for July 15, 2015
NLNK
Jul 15, 2015 | 07:14 EDT
Cantor increased its price target on NewLink, citing positive developments at the company's Investor Day, including an estimated median OS assumption for the IMPRESS trial, new clinical programs and potential data this year from the company's indoximod and IDO/TDO programs. The firm thinks the company sits in a virtual "sweet spot" of oncology drug development and reiterates a Buy rating.
News For NLNK From the Last 2 Days
There are no results for your query NLNK